Asklepion   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Baltimore MD United States (2006)

Organization Overview

First Clinical Trial
2006
NCT00428935
First Marketed Drug
2015
cholic acid (cholbam)
First NDA Approval
2015
cholic acid (cholbam)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Asklepion Pharmaceuticals, LLC | Asklepios Biopharmaceutical, Inc. | RTRX

Active Ingredients

Marketed Drugs (2)

cholic acid (cholbam) (2015 NDA)

oxytocin (syntocinon)

Drugs in Phase 3 Trials (5)

citrulline (6 trials)

magnesium (1 trial)

potassium chloride (klor-con) (1 trial)

sodium acetate (1 trial)

sodium gluconate (1 trial)

Drugs in Phase 2 Trials (2)

lion-101 (1 trial)

nan-101 (2 trials)

Drugs in Phase 1 Trials (1)

raav2.5-cmv-minidystrophin (1 trial)

Indications

Approved Indications


 

Peroxisomal Disorders

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Cardiovascular Diseases (Phase 1)

Congenital Abnormalities (Phase 3)

Endocardial Cushion Defects (Phase 2)

Heart Defects, Congenital (Phase 3)

Heart Diseases (Phase 1)

Heart Failure (Phase 1)

Heart Failure, Diastolic (Phase 1)

Heart Failure, Systolic (Phase 1)

Heart Septal Defects (Phase 2)

Heart Septal Defects, Atrial (Phase 2)

Heart Septal Defects, Ventricular (Phase 2)

Hypertension, Pulmonary (Phase 3)

Lung Injury (Phase 3)

Muscular Dystrophies (Phase 1)

Muscular Dystrophy, Duchenne (Phase 1)

Myocardial Ischemia (Phase 1)

Respiratory Distress Syndrome (Phase 3)

Respiratory Insufficiency (Phase 2)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 8